Please assess the completion status of the following clinical trial:

Trial Title: Sodium Oxybate in Schizophrenia With Insomnia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18-45 with a DSM-IV diagnosis of schizophrenia and insomnia related to schizophrenia, confirmed by a structured interview (SCID).~Exclusion Criteria:~* Lack of capacity to give informed consent (capacity is determined by a licensed member of the treatment team).~* Unstable medical illness.~* Diagnosis of restless leg syndrome, a seizure disorder, uncontrolled hypertension, unstable cardiac illness, or obstructive sleep apnea.~* Pregnancy or lack of adequate birth control.~* History of substance dependence disorder.~* Current treatment with valproic acid.~* Succinic semialdehyde dehydrogenase deficiency (SSADH).~* Persistent need for treatment with benzodiazepines, barbiturates, opiates or other sedative hypnotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Sodium oxybate (Type: EXPERIMENTAL): Active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).